ClinicalTrials.gov record
Terminated Phase 1 Interventional

Study of INCA 0186 in Subjects With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT04989387

Public ClinicalTrials.gov record NCT04989387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

Study identification

NCT ID
NCT04989387
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Incyte Corporation
Industry
Enrollment
57 participants

Conditions and interventions

Interventions

  • INCA00186 Drug
  • INCB106385 Drug
  • Retifanlimab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 3, 2021
Primary completion
Sep 18, 2024
Completion
Sep 18, 2024
Last update posted
Sep 1, 2025

2021 – 2024

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
The Angeles Clinic and Research Institute Los Angeles California 90025
Emory University Atlanta Georgia 30322
University of Maryland-Greenebaum Cancer Center Baltimore Maryland 21201
Hackensack University Medical Center Hackensack New Jersey 07601
Carolina Bio-Oncology Institute, Pllc Huntersville North Carolina 28078
Vanderbilt Medical Center Nashville Tennessee 37232
Md Anderson Cancer Center Houston Texas 77030
South Texas Accelerated Research Therapeutics San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04989387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 1, 2025 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04989387 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →